What is Better Therapeutics Financial Strength?
Better Therapeutics has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Better Therapeutics did not have earnings to cover the interest expense.
As of today, Better Therapeutics's Altman Z-Score is 0.00.
Competitive Comparison of Better Therapeutics's Financial Strength
For the Biotechnology subindustry, Better Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Better Therapeutics's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Better Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Better Therapeutics's Financial Strength falls into.
Better Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Better Therapeutics's Interest Expense for the
months ended in Sep. 2023 was $-0.52 Mil. Its Operating Income for the
months ended in Sep. 2023 was $-5.34 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $7.72 Mil.
Better Therapeutics's Interest Coverage for the quarter that ended in Sep. 2023 is
| Better Therapeutics did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Better Therapeutics's Debt to Revenue Ratio for the quarter that ended in Sep. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Better Therapeutics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Better Therapeutics (Better Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
548 Market Street, Suite 49404, San Francisco, CA, USA, 94104
Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.
Executives
| Elder Granger |
director |
5176 S. LEWISTON WAY, CENTENNIAL CO 80015 |
| Mark A. Berman |
officer: Chief Medical Officer |
548 MARKET STREET, #49404, SAN FRANCISCO CA 94104 |
| Geoffrey M. Parker |
director |
15 RIORDAN PLACE, MENLO PARK CA 94025 |
| Frank Karbe |
director, officer: See Remarks |
C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
| David P Perry |
director, 10 percent owner, officer: See Remarks |
1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303 |
| Andrew J. Armanino |
director |
C/O CALIFORNIA BANCORP, 1300 CLAY STREET, FIFTH FLOOR, OAKLAND CA 94612 |
| Georgianna Maule-ffinch 2015 Trust |
10 percent owner |
C/O BETTER THERAPEUTICS, INC., 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104 |
| Mark Heinen |
officer: See Remarks |
548 MARKET STREET, #49404, SAN FRANCISCO CA 94104 |
| Risa J Lavizzo-mourey |
director |
GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661 |
| Kevin J Appelbaum |
director, 10 percent owner, officer: Chief Executive Officer |
4160 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568 |
| Suying Liu |
director |
311 WEST 43RD STREET, 12TH FLOOR, NEW YORK NY 10036 |
| Justin Zamirowski |
officer: Chief Commercial Officer |
548 MARKET STREET, #49404, SAN FRANCISCO CA 94104 |
| Kristin Wynholds |
officer: Chief Product Officer |
548 MARKET STREET, #49404, SAN FRANCISCO CA 94104 |
| Richard H Carmona |
director |
1221 BROADWAY, OAKLAND CA 94612 |
| David P. Perry 2015 Trust |
10 percent owner |
548 MARKET STREET, #49404, SAN FRANCISCO CA 94104 |
Better Therapeutics (Better Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BTTX has been successfully added to your